IRAK4-IN-1

SKU: orb1303103

Description

IRAK4-IN-1

Research Area

Immunology & Inflammation, Signal Transduction

Key Properties

• CAS Number: 1820787-94-7
• MW: 337.42
• Purity: 98.18%
• Formula: C₁₉H₂₃N₅O
• SMILES: N#Cc1ccc2ncnc(N[C@H]3CC[C@@H](CC3)N3CCOCC3)c2c1
• Target: IRAK
• Solubility: H2O:< 0.1 mg/mL (insoluble);10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (2.96 mM);DMSO:1 mg/mL (2.96 mM)

Bioactivity

• Target IC50:
  IRAK4:7 nM.
• In Vivo:
  Oral pharmacokinetic analyses of IRAK4-IN-1 indicate that it possesses a high bioavailability of 73%, along with low plasma clearance (Clp=22 mL/min/kg), which culminates in a stable half-life of 1.3 hours.
• In Vitro:
  The in vitro metabolic stability profile of IRAK4-IN-1 was assessed, yielding an EC50 of 2300 nM in rat whole blood (RWB).
• Animal Research:
  In the TLR driven in vivo model, female Lewis rats are dosed with either vehicle or IRAK4-IN-1 (Compound 23; 3, 10, 30, and 100 mg/kg; p.o.) dosed at 1 h prior to stimulation with Resiquimod, R848 (5 mg/kg, IP). At 1.5 h post R848 stimulation, blood samples are obtained from the animals and cytokine levels are measured.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, Interleukin-1 receptor associated kinase, IL-1R associated kinase, IRAK, IRAK-4, IRAK4 IN 1, IRAK4IN1, IRAK-4-IN-1, IRAK4-IN-1, Inhibitor

Compound Identifiers

PubChem CID

118475349